A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study To Evaluate The Efficacy And Safety Of DA-302168S Tablets In Overweight/Obese Subjects
Latest Information Update: 07 May 2025
At a glance
- Drugs DA 302168 S (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Chengdu DIAO Pharmaceutical Group
Most Recent Events
- 07 May 2025 New trial record